Preoperative gemcitabine-nab-paclitaxel (G-NP) for (borderline) resectable (BLR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC): Feasibility results and early response monitoring by Diffusion-Weighted (DW) MR.
Jean‐Luc Van Laethem(Deventer Ziekenhuis), Raphaël Maréchal(Université Libre de Bruxelles), Marc Peeters(University of Antwerp), Antonino Ceratti(Cliniques Universitaires Saint-Luc), Anne Demols, Gontran Verset, Mina Komuta(Cliniques Universitaires Saint-Luc), Axelle Ghilain(Université Libre de Bruxelles), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Pieter Demetter(Université Libre de Bruxelles), Ivan Borbath, Laurence Annet(Cliniques Universitaires Saint-Luc), Francesco Puleo(Erasmus Hospital)
Cited by 12
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k